An official website of the United States government
September 29, 2026 Edition
News
Antiviral drug did not improve Long COVID symptoms
A clinical trial for Long COVID found that treating patients with a common antiviral drug for up to 25 days did not improve symptoms.
News
tRNA treatment may help restore cystic fibrosis proteins
Lipid nanoparticles delivering engineered transfer RNA restored functional proteins in cell and animal models of cystic fibrosis.
News
Bacterial infection may alter developing gut
C. difficile bacteria caused lasting changes to cells in the intestines of newborn mice.
Displaying 463 - 469 of 912
Cancer cells drain energy from immune cells
Researchers found that cancer cells use straw-like nanotubes to siphon mitochondria from immune cells, essentially draining their energy.
Brain receptor linked to puberty and growth
Researchers identified a brain receptor that links childhood nutrition to the timing of puberty and growth.
Scientists identify a culprit for chronic itch
The discovery of an immune substance that sensitizes and enhances the activity of itch-sensing neurons suggests a treatment strategy for persistent itchy skin conditions.
Searching for new antibiotics in the human body
Researchers identified tiny pieces of protein produced by the body that could be synthesized and potentially developed into new antibiotics.
Repurposing drugs to treat age-related macular degeneration
Researchers found that the antidepressant fluoxetine blocks the inflammation that leads to dry age-related macular degeneration, or AMD, a common cause of vision loss.
SARS-CoV-2 infection of the inner ear
Researchers found that SARS-CoV-2 can infect inner ear cells, which could explain the hearing and balance issues in some COVID-19 patients.
Therapy has long-lasting benefits for children with cerebral palsy
Sixty hours of a therapy called CIMT led to significant improvements in hand and arm function among children with cerebral palsy in a randomized trial.